Teaching Tolerance to Address Autoimmune Diseases

COUR CEO John Puisis and COUR Vice President of Research Adam Elhofy discuss how the company’s immune-modifying nanoparticles work, how the approach preserves the immune response, and its partnership with Takeda focused on celiac disease.